Hi, what are you looking for?
Jewish Business News
Search results for " Erez Vigodman"
Business
Teva bought its 4.6% stake in Mylan at prices of $69-74 per share. the share price is down sharply in premarket trading.
Business
The deal, the largest ever acquisition by an Israeli company, is in cash and shares.
Mergers & Acquisitions
Teva will pay over $45 billion for the botox maker unit, report the "Wall Street Journal."
Business
Dutch Stichting Foundation notified Mylan that it has exercised its call option to acquire 488, 388, 431 Mylan preferred shares pursuant to the...
Business
The groups told the US FTC: Increased consolidation has already led to higher prices and to generic drug shortages.
Business
As Israel’s biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food...
Business
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Erez Vigodman said today, “If the Mylan Pharmaceuticals shareholders support the acquisition of...
Business
Erez Vigodman: Size isn't everything; it's important to be better.
Business
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has completed first step to buy its rival Mylan N.V. (Nasdaq: MYL). The Israeli giant announced...
Business
Teva says it will seek ‘further appellate review’